A.A@a_a_freeThis is what one of the best BD in IBD and immunology said about the space. That's why $SYRE and $ORKA are expensive and probably at least one of them will be taken by 2027 if not both. When you see the number of companies who recently went IPO, private companies and the recent
Bioinvestor24@bioinvestor24$ABBV CEO and mgt just confirmed their focus in IBD and immunology on combinations and extended half life and as being the next frontier $SYRE CEO affirms his assets are in a different tier vs Abbv .. co formulation volumes , extended half life and exposure.
